Ocuphire Pharma presents APX3330 ZETA-1 clinical data at ADA conference

Ocuphire Pharma announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment-Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83rd Scientific Sessions of the American Diabetes Association, ADA, in San Diego, CA on Saturday, June 24, 2023. “We were pleased to present our ZETA-1 data on oral APX3330 at the world’s largest diabetes meeting that features important diabetic advances,” said Rick Rodgers, Interim Chief Executive Officer. “In this trial, APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy, as measured by the percentage of subjects with binocular 3-step worsening in DRSS, our anticipated Phase 3 primary endpoint. Compared to the current intravitreal injection options, a non-invasive convenient oral therapy that prevents disease progression could shift the treatment paradigm and broaden the prescriber base to include not only eye care physicians but primary care and endocrinologists. We look forward to an End of Phase 2 meeting with the FDA to confirm the Phase 3 study design and continue advancing APX3330 towards potential approval.”